News in brief - January 2015 (updated)

Other new launches, licence changes and updates relevant to general practice.

The cobicistat component of Rezolsta boosts levels of darunavir in the blood and does not require concomitant ritonavir, potentially reducing the pill burden
The cobicistat component of Rezolsta boosts levels of darunavir in the blood and does not require concomitant ritonavir, potentially reducing the pill burden
  • Victoza (liraglutide) can now be used in diabetic patients with moderate renal impairment (CrCl 30–59ml/min). 
  • Eplerenone tablets (25mg and 50mg) are now available as a generic for the treatment of patients with LVEF ≤40% and clinical evidence of heart failure after MI, and those with chronic heart failure and LVEF ≤30%.
  • Janssen has launched Rezolsta, a fixed-dose combination tablet containing the protease inhibitor darunavir and the pharmacoenhancer cobicistat, for the treatment of HIV infection.
  • Aripiprazole tablets are now available as a generic for the treatment of schizophrenia in adults.
  • The oral androgen receptor antagonist Xtandi (enzalutamide) is now licensed for metastatic castration-resistant prostate cancer in men who are asymptomatic or mildly symptomatic and in whom chemotherapy is not yet indicated.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from intelog

New antibiotic prescribing guidance issued for pneumonia

New antibiotic prescribing guidance issued for pneumonia

NICE has published antimicrobial prescribing guidelines...

intelog summary of NICE COPD guidance updated

intelog summary of NICE COPD guidance updated

Prescribers can now consult the quick-reference intelog...

Soft-mist inhaler now available as reusable device

Soft-mist inhaler now available as reusable device

Respimat is now available as a reusable inhaler that...

NICE recommends 'innovative' treatment for type I diabetes

NICE recommends 'innovative' treatment for type I diabetes

Dapagliflozin (Forxiga) has been approved for routine...